2023
Anke Augspach, Kyle D. Drake, Luca Roma, Ellen Qian, Se Ri Lee, Declan Clarke, Sushant Kumar, Muriel Jaquet, John Gallon, Marco Bolis, Joanna Triscott, José A. Galvan, Yu Chen, Georges N. Thalmann, Marianna Kruithof-de Julio, Jean-Philippe P. Theurillat, Stefan Wuchty, Mark Gerstein, Salvatore Piscuoglio, Rahul N. Kanadia, Mark A. Rubin. Minor intron splicing is critical for survival of lethal prostate cancer. Molecular Cell. June 2023 doi:10.1016/j.molcel.2023.05.017
J. Gallon*, A. Rodriguez-Calero*, A. Benjak, D. Akhoundova, S. Maletti, U. Amstutz, E. Hewer, V. Genitsch, A. Fleischmann, E.J. Rushing, R. Grobholz, I. Fischer, W. Jochum, G. Cathomas, A.O. Osunkoya, L. Bubendorf, H. Moch, G. Thalmann, F.Y. Feng, S. Gillessen, C.K.Y. Ng, M. A. Rubin and S. Piscuoglio. DNA methylation landscapes of prostate cancer brain metastasis are shaped by early driver genetic alterations. Cancer Research. 2023 Februar *Equal contribution.
Triscott, J., Reist, M., Küng. L, Moselle, F.C., Lehner, M., Gallon, J., Ravi, A., Arora, G.K., de Brot, S., Lundquist, M., Gallart-Ayala, H., Ivanisevic, J., Piscuoglio, S., Cantley, L.C., Emerling, B.M., and Rubin, M.A. “PI5P4Kα supports prostate cancer metabolism and exposes a survival vulnerability during androgen receptor (AR) inhibition.” (2023) Science Advances 9(5): eade8641.
2022
Pauli C, De Boni L, Pauwels JE, Chen Y, Planas-Paz L, Shaw R, Emerling BM, Grandori C, Hopkins BD, Rubin MA. A Functional Precision Oncology Approach to Identify Treatment Strategies for Myxofibrosarcoma Patients. Mol Cancer Res. 2022 Feb;20(2):244-252. PMID: 34728552.
Rodriguez-Calero A, Gallon J, Akhoundova D, Maletti S, Ferguson A, Cyrta J, Amstutz U, Garofoli A, Paradiso V, Tomlins S, Hewer E, Genitsch V, Fleischmann A, Vassella E, Rushing E, Grobholz R, Fischer I, Jochum W, Cathomas G, Osunkoya A, Bubendorf L, Moch H, Thalmann G, Ng C, Gillessen S, Piscuoglio S, Rubin MA. Alterations in Homologous Recombination Repair Genes in Prostate Cancer Brain Metastases. Nature Communications. 2022 May 3; 13(1):2400. PMID: 35504881.
Orlando F, Romanel A, Trujillo B, Sigouros M, Wetterskog D, Quaini O, Leone G, Xiang JZ, Wingate A, Tagawa S, Jayaram A, Linch M; PEACE Consortium, Jamal-Hanjani M, Swanton C, Rubin MA, Wyatt AW, Beltran H, Attard G, Demichelis F. Allele-informed copy number evaluation of plasma DNA samples from metastatic prostate cancer patients: the PCF_SELECT consortium assay. NAR Cancer. 2022 May 27;4(2):zcac016. PMID: 35664542.
Kashani E, Schnidrig D, Hashemi Gheinani A, Ninck MS, Zens P, Maragkou T, Baumgartner U, Schucht P, Rätsch G, Rubin MA, Berezowska S, Ng CKY, Vassella E; SOCIBP consortium. Integrated longitudinal analysis of adult grade 4 diffuse gliomas with long-term relapse interval revealed upregulation of TGF-β signaling in recurrent tumors. Neuro Oncol. 2022 Sep 17:noac220. Epub ahead of print. Erratum in: Neuro Oncol. 2022 Dec 16;: PMID: 36124685.
Janowczyk A, Baumhoer D, Dirnhofer S, Grobholz R, Kipar A, de Leval L, Merkler D, Michielin O, Moch H, Perren A, Rottenberg S, Rubbia-Brandt L, Rubin MA, Sempoux C, Tolnay M, Zlobec I, Koelzer VH; Swiss Digital Pathology Consortium (SDiPath). Towards a national strategy for digital pathology in Switzerland. Virchows Arch. 2022 Oct;481(4):647-652. Epub 2022 May 27. PMID: 35622144.
Vasciaveo A, Arriaga JM, Nunes de Almeida F, Zou M, Douglass EF, Picech F, Shibata M, RodriguezCalero A, de Brot S, Mitrofanova A, Chua CW, Karan C, Realubit R, Pampou S, Kim JY, Afari SN, Mukhammadov T, Zanella L, Corey E, Alvarez MJ, Rubin MA, Shen MM, Califano A, Abate-Shen C. OncoLoop: A network-based precision cancer medicine framework. Cancer Discov. 2022 Nov 14:CD-22-0342. Epub ahead of print. PMID: 36374194.
Zeng Q, Saghafinia S, Chryplewicz A, Fournier N, Christe L, Xie YQ, Guillot J, Yucel S, Li P, Galván JA, Karamitopoulou E, Zlobec I, Ataca D, Gallean F, Zhang P, Rodriguez-Calero JA, Rubin MA, Tichet M, Homicsko K, Hanahan D. Aberrant hyperexpression of the RNA binding protein FMRP in tumors mediates immune evasion. Science. 2022 Nov 18;378(6621):eabl7207. PMID: 36395212.
Gillessen S et al. Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/Highrisk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022. Eur Urol. 2022 Dec 6:S0302-2838(22)02789-0. Epub ahead of print. PMID: 36494221.
Cyrta J, Rosiene J, Bareja R, Kudman S, Al Zoughbi W, Motanagh S, Wilkes DC, Eng K, Zhang T, Sticca E, Mathew S, Rubin MA, Sboner A, Elemento O, Rubin BP, Imielinski M, Mosquera JM. Wholegenome characterization of myoepithelial carcinomas of the soft tissue. Cold Spring Harb Mol Case Stud. 2022 Dec 28;8(7):a006227. PMID: 36577525.
Cotter K, Rubin MA. The evolving landscape of prostate cancer somatic mutations. Prostate. 2022 Aug; 82 Suppl 1(Suppl 1):S13-S24. PMID: 35657155.
Akhoundova D, Rubin MA. Clinical application of advanced multi-omics tumor profiling: Shaping precision oncology of the future. Cancer Cell. 2022 Sep 12;40(9):920-938. PMID: 36055231.
Berney DM, Cree I, Rao V, Moch H, Srigley JR, Tsuzuki T, Amin MB, Comperat EM, Hartmann A, Menon S, Netto GJ, Rubin MA, Turajlic S, Raspollini MR, Tickoo SK. An introduction to the WHO 5th edition 2022 classification of testicular tumours. Histopathology. 2022 Oct;81(4):459-466. PMID: 35502823.
Lobo J, Ohashi R, Amin MB, Berney DM, Compérat EM, Cree IA, Gill AJ, Hartmann A, Menon S, Netto GJ, Raspollini MR, Rubin MA, Tan PH, Tickoo SK, Tsuzuki T, Turajlic S, Zhou M, Srigley JR, Moch H. WHO 2022 landscape of papillary and chromophobe renal cell carcinoma. Histopathology. 2022 Oct;81(4):426-438. PMID: 35596618.
Kench JG, Amin MB, Berney DM, Compérat EM, Cree IA, Gill AJ, Hartmann A, Menon S, Moch H, Netto GJ, Raspollini MR, Rubin MA, Tan PH, Tsuzuki T, Turjalic S, van der Kwast TH, Zhou M, Srigley JR. WHO Classification of Tumours fifth edition: evolving issues in the classification, diagnosis, and prognostication of prostate cancer. Histopathology. 2022 Oct;81(4):447-458. PMID: 35758185.
Compérat E, Amin MB, Berney DM, Cree I, Menon S, Moch H, Netto GJ, Rao V, Raspollini MR, Rubin MA, Srigley JR, Tan PH, Tickoo SK, Turajlic S, Tsuzuki T. What's new in WHO fifth edition - urinary tract. Histopathology. 2022 Oct;81(4):439-446. PMID: 35942645.
Moch H, Amin MB, Berney DM, Compérat EM, Gill AJ, Hartmann A, Menon S, Raspollini MR, Rubin MA, Srigley JR, Hoon Tan P, Tickoo SK, Tsuzuki T, Turajlic S, Cree I, Netto GJ. The 2022 World Health Organization Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours. Eur Urol. 2022 Nov;82(5):458-468. PMID: 35853783.
Netto GJ, Amin MB, Berney DM, Compérat EM, Gill AJ, Hartmann A, Menon S, Raspollini MR, Rubin MA, Srigley JR, Hoon Tan P, Tickoo SK, Tsuzuki T, Turajlic S, Cree I, Moch H. The 2022 World Health Organization Classification of Tumors of the Urinary System and Male Genital Organs-Part B: Prostate and Urinary Tract Tumors. Eur Urol. 2022 Nov;82(5):469-482. PMID: 35965208.
Ferguson AM, Rubin MA. Lineage plasticity in prostate cancer: Looking beyond intrinsic alterations. Cancer Lett. 2022 Nov 1;548:215901. PMID: 36075486.
Akhoundova D, Feng FY, Pritchard CC, Rubin MA. Molecular Genetics of Prostate Cancer and Role of Genomic Testing. Surg Pathol Clin. 2022 Dec;15(4):617-628. PMID: 36344179.
Burke, J.E., Triscott, J., Emerling, B.M., and Hammond, G.R.V. “Beyond PI3Ks: targeting phosphoinositide kinases in disease.” (2022) Nature Reviews Drug Discovery, 14:1-30.
2021
Ravi, A., Palamiuc, L., *Loughran, R., *Triscott, J., Arora, G., Kumar, A., Tieu, V., Pauli, C., Reist, M., Lew, R., Houlihan, S., Fellmann, C., Metallo, C., Rubin, M.A., Emerling, B. “PI5P4Ks drive metabolic homeostasis through peroxisome-mitochondria interplay.” (2021) Developmental cell 56(11): 1661-1676.
Ryman-Tubb T, Lothion-Roy JH, Metzler VM, Harris AE, Robinson BD, Rizvanov AA, Jeyapalan JN, James VH, England G, Rutland CS, Persson JL, Kenner L, Rubin MA, Mongan NP, de Brot S. Comparative pathology of dog and human prostate cancer. Vet Med Sci. 2022 Jan;8(1):110-120. Epub 2021 Oct 10. PMID: 34628719.
2020
Cyrta J, Augspach A, de Filippo MR, Prandi D, Thienger P, Benelli M, Cooley V, Bareja R, Wilkes D, Chae S-S, Cavaliere P, Dephure N, Uldry A-C, Lagache SB, Roma L, Cohen S, Jaquet M, Brandt LP, Alshalalfa M, Sboner A, Feng F, Wang S, Beltran H, Lotan T, Spahn M, Kruithof-de Julio M, Chen Y, Ballman KV, Demichelis F, Piscuoglio S, Rubin MA*. Role of Specialized Composition of SWI/SNF Complexes in Prostate Cancer Lineage Plasticity. Nat Commun. 2020; 11: 5549. https://doi.org/10.1038/s41467-020-19328-1 *Corresponding Author
Arriaga J, Panja S, Alshalalfa M, Zhao J, Zou M, Giacobbe A, Madubata CJ, Kim JY, Rodriguez A, Coleman I, Virk RK, Hibshoosh H, Ertunc O, Ozbek B, Fountain J, Karnes RJ, Luo J, Antonarakis ES, Nelson PS, Feng FY, Rubin MA, De Marzo AM, Rabadan R, Sims PA, Mitrofanova A, Abate-Shen C. A MYC and RAS co-activation signature in localized prostate cancer drives bone metastasis and castration resistance. Nat Cancer. 2020; https://doi.org/10.1038/s43018-020-00125-0
Bailey MH, Meyerson WU, Dursi LJ; Wang L, Dong G, Liang W, Weerasinghe A, Li S, Kelso S, MC3 Working Group, PCAWG novel somatic mutation calling methods working group, Saksena G, Ellrott K, Wendl MC, Wheeler DA, Getz G, Simpson JT, Gerstein MB, Ding Li, PCAWG Consortium. Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples. Nat Commun. 2020; 11: 4748. https://doi.org/10.1038/s41467-020-18151-y
Li CH, Prokopec SD, Sun RX, Yousif F, Schmitz N, PCAWG Tumour Subtypes and Clinical Translation, Boutros PC, PCAWG Consortium. Sex differences in oncogenic mutational processes. Nat Commun. 2020;11: 4330. https://doi.org/10.1038/s41467-020-17359-2
Aurélie Auguste, Félix Blanc-Durand, Marc Deloger, Audrey Le Formal, Rohan Bareja, David C. Wilkes, Catherine Richon, Béatrice Brunn, Olivier Caron, Mojgan Devouassoux-Shisheboran, Sébastien Gouy, Philippe Morice, Enrica Bentivegna, Andrea Sboner, Olivier Elemento, Mark A. Rubin, Patricia Pautier, Catherine Genestie, Joanna Cyrta, Alexandra Leary. Small Cell Carcinoma of the Ovary, Hypercalcemic Type (SCCOHT) beyond SMARCA4 Mutations: A Comprehensive Genomic Analysis. Cells. 2020 Jun 19; 9(6), 1496; https://doi.org/10.3390/cells9061496
Pisapia DJ, Ohara K, Bareja R, Wilkes DC, Hissong E, Croyle JA, Kim JH, Saab J, MacDonald TY, Beg S, O'Reilly C, Kudman S; Rubin MA, Elemento O, Sboner A, Greenfield J, Mosquera JM. Fusions involving BCOR and CREBBP are rare events in infiltrating glioma. Acta Neuropathol Commun 2020 Jun 3;8(1):80. https://doi.org/10.1186/s40478-020-00951-4
ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium [1341 authors]. Pan-cancer analysis of whole genomes. Nature. 2020 Feb;578(7793):82-93. https://doi.org/10.1038/s41586-020-1969-6
Rheinbay E, Nielsen MM, Abascal F, Wala JA, Shapira O, Tiao G, Hornshøj H, Hess JM, Juul RI, Lin Z, Feuerbach L, Sabarinathan R, Madsen T, Kim J, Mularoni L, Shuai S, Lanzós A, Herrmann C, Maruvka YE, Shen C, Amin SB, Bandopadhayay P, Bertl J, Boroevich KA, Busanovich J, Carlevaro-Fita J, Chakravarty D, Chan CWY, Craft D, Dhingra P, Diamanti K, Fonseca NA, Gonzalez-Perez A, Guo Q, Hamilton MP, Haradhvala NJ, Hong C, Isaev K, Johnson TA, Juul M, Kahles A, Kahraman A, Kim Y, Komorowski J, Kumar K, Kumar S, Lee D, Lehmann KV, Li Y, Liu EM, Lochovsky L, Park K, Pich O, Roberts ND, Saksena G, Schumacher SE, Sidiropoulos N, Sieverling L, Sinnott-Armstrong N, Stewart C, Tamborero D, Tubio JMC, Umer HM, Uusküla-Reimand L, Wadelius C, Wadi L, Yao X, Zhang CZ, Zhang J, Haber JE, Hobolth A, Imielinski M, Kellis M, Lawrence MS, von Mering C, Nakagawa H, Raphael BJ, Rubin MA, Sander C, Stein LD, Stuart JM, Tsunoda T, Wheeler DA, Johnson R, Reimand J, Gerstein M, Khurana E, Campbell P, López-Bigas N, PCAWG Drivers and Functional Interpretation Working Group [128 authors], PCAWG Structural Variation Working Group [73 authors], Weischenfeldt J, Beroukhim R, Martincorena I, Pedersen JS, Getz G , PCAWG Consortium. Analyses of non-coding somatic drivers in 2,658 cancer whole genomes. Nature. 2020 Feb;578(7793):102-111. https://doi.org/10.1038/s41586-020-1965-x
Reyna MA, Haan D, Paczkowska M, Verbeke LPC, Vazquez M, Kahraman A, Pulido-Tamayo S, Barenboim J, Wadi L, Dhingra P, Shrestha R, Getz G, Lawrence MS, Pedersen JS, Rubin MA, Wheeler DA, Brunak S, Izarzugaza JMG, Khurana E, Marchal K, von Mering C, Sahinalp SC, Valencia A, PCAWG Drivers and Functional Interpretation Working Group [103 authors], Raphael BJ, PCAWG Consortium. Pathway and network analysis of more than 2500 whole cancer genomes. Nature Communications. 2020 February 05; 11(1):729. https://doi.org/10.1038/s41467-020-14367-0
Carlevaro-Fita J, Lanzós A, Feuerbach L, Hong C, Mas-Ponte D, Pedersen JS, PCAWG Drivers and Functional Interpretation Working Group [130 authors], Johnson R, PCAWG Consortium. Cancer LncRNA Census reveals evidence for deep functional conservation of long noncoding RNAs in tumorigenesis. Communications Biology. 2020 February 05; 3(1):56. https://doi.org/10.1038/s42003-019-0741-7
Shuai S, PCAWG Drivers and Functional Interpretation Working Group [128 authors], Gallinger S, Stein L, PCAWG Consortium. Combined burden and functional impact tests for cancer driver discovery using DriverPower. Nature Communications. 2020 February 05; 11(1):734. https://doi.org/10.1038/s41467-019-13929-1
Jiao W, Atwal G, Polak P, Karlic R, Cuppen E, PCAWG Tumor Subtypes and Clinical Translation Working Group [48 authors], Danyi A, de Ridder J, van Herpen C, Lolkema MP, Steeghs N, Getz G, Morris Q, Stein LD, PCAWG Consortium. A deep learning system accurately classifies primary and metastatic cancers using passenger mutation patterns. Nature Communications. 2020 February 05; 11(1):728. https://doi.org/10.1038/s41467-019-13825-8
Paczkowska M, Barenboim J, Sintupisut N, Fox NS, Zhu H, Abd-Rabbo D, Mee MW, Boutros PC, PCAWG Drivers and Functional Interpretation Working Group [126 authors], Reimand J, PCAWG Consortium. Integrative pathway enrichment analysis of multivariate omics data. Nature Communications. 2020 February 05; 11(1):735. https://doi.org/10.1038/s41467-019-13983-9
Lotan TL, Tomlins SA, Bismar TA, Van der Kwast TH, Grignon D, Egevad L, Kristiansen G, Pritchard CC, Rubin MA, Bubendorf L. Report from the International Society of Urological Pathology (ISUP) Consultation Conference on Molecular Pathology of Urogenital Cancers: I. Molecular Biomarkers in Prostate Cancer. American Journal of Surgical Pathology. 2020 Feb 10. doi: 10.1097. DOI: 10.1097/pas.0000000000001450
2019
Beltran H, Oromendia C, Danila DC, Montgomery B, Hoimes C, Szmulewitz RZ, Vaishampayan U, Armstrong AJ, Stein M, Pinski J, et al. A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers. Clinical Cancer Reseach. 2019; 25(1):43-51. doi: 10.1158/1078-0432.CCR-18-1912
Skvortsova K, Masle-Farquhar E, Luu P-L, Song JZ, Qu W, Zotenko E, Gould CM, Du Q, Peters TJ, Colino-Sanguino Y, Pidsley R, Nair SS, Khoury A, Smith GC, Miosge LA, Reed JH, Kench JG, Rubin MA, Horvath L, Bogdanovic O, Lim SM, Polo JM, Goodnow CC, Stirzaker C, Clark SJ. DNA Hypermethylation encroachment at CpG island borders in cancer is predisposed by H3K4 monomethylation Patterns. Cancer Cell. 2019 Feb 11; 35(2):297-314.e298. https://doi.org/10.1016/j.ccell.2019.01.004
Karkampouna S, Grosjean J, Klima I, Genitsch V, Sboner A, K. Y. Ng C, De Filippo MR, Piscuoglio S, Spahn M, Rubin MA, Thalmann GN, Kruithof-De Julio M. Establishment of an androgen-sensitive patient derived xenograft model of prostate cancer. European Urology Supplements. 2019 March 1; 18(1):e1154. https://doi.org/10.1016/S1569-9056(19)30831-0
Lee RS, Zhang L, Berger A, Lawrence MG, Song J, Niranjan B, Davies RG, Lister NL, Sandhu SK, Rubin MA, Risbridger GP, Taylor RA, Rickman DS, Horvath LG, Daly RJ. Characterization of the ERG-regulated kinome in prostate cancer identifies TNIK as a potential therapeutic target. Neoplasia. 2019 April 01; 21(4):389-400. https://doi.org/10.1016/j.neo.2019.02.005
Abida W, Cyrta J, Heller G, Prandi D, Armenia J, Coleman I, Cieslik M, Benelli M, Robinson D, Van Allen EM, et al. Genomic correlates of clinical outcome in advanced prostate cancer. PNAS. 2019. doi: 10.1073/pnas.1902651116
Augello MA, Liu D, Deonarine LD, Robinson BD, Huang D, Stelloo S, Blattner M, Doane AS, Wong EW, Chen Y, et al. CHD1 Loss Alters AR Binding at Lineage-Specific Enhancers and Modulates Distinct Transcriptional Programs to Drive Prostate Tumorigenesis. Cancer Cell. 2019; 35(4):603-617. doi: 10.1016/j.ccell.2019.03.001
Persi E, Prandi D, Wolf YI, Pozniak Y, Barnabas GD, Levanon K, Barshack I, Barbieri C, Gasperini P, Beltran H, Faltas BM, Rubin MA, Geiger T, Koonin EV, Demichelis F, Horn D. Proteomic and genomic signatures of repeat instability in cancer and adjacent normal tissues. PNAS. 2019 August 20, 116 (34) 16987-16996. https://doi.org/10.1073/pnas.1908790116
Lou S, Cotter KA, Li T, Liang J, Mohsen H, Liu J, Zhang J, Cohen S, Xu J, Yu H, Rubin MA, Gerstein M. GRAM: A GeneRAlized Model to predict the molecular effect of a non-coding variant in a cell-type specific manner. PLOS Genetics. 2019 Aug 30; 15(8):e1007860. https://doi.org/10.1371/journal.pgen.1007860
2018
Aytes A, Giacobbe A, Mitrofanova A, Ruggero K, Cyrta J, Arriaga J, Palomero L, Farran-Matas S, Rubin MA, Shen MM, Califano A, Abate-Shen C. NSD2 is a conserved driver of metastatic prostate cancer progression. Nature Communications. 2018;9(1):5201. doi: 10.1038/s41467-018-07511-4
Boysen G, Rodrigues DN, Rescigno P, Seed G, Dolling D, Riisnaes R, Crespo M, Zafeiriou Z, Sumanasuriya S, Bianchini D, et al. SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity. Clinical Cancer Research. 2018; 24(22):5585-5593. doi: 10.1158/1078-0432.CCR-18-0937
Nava Rodrigues D, Rescigno P, Liu D, Yuan W, Carreira S, Lambros MB, Seed G, Mateo J, Riisnaes R, Mullane S, et al. Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer. The Journal of Clinical Investigation. 2018; 128(10):4441-4453. doi: 10.1172/JCI121924
Cotter K, Rubin MA; Sequence of events in prostate cancer Nature 2018 Aug 24, doi: 10.1038/d41586-018-06029-5
Hopkins BD, Pauli C, Du X, Wang DG, Li X, Wu D, Amadiume SC, Goncalves MD, Hodakoski C, Lundquist MR, Bareja R, Ma Y, Harris EM, Sboner A, Beltran H, Rubin MA, Mukherjee S, Cantley LC. Suppression of insulin feedback enhances the efficacy of PI3K inhibitors. Nature. 2018; 560(7719):499-503. doi: 10.1038/s41586-018-0343-4
Puca L, Bareja R, Prandi D, Shaw R, Benelli M, Karthaus WR, Hess J, Sigouros M, Donoghue A, Kossai M, et al. Patient derived organoids to model rare prostate cancer phenotypes. Nature Communications. 2018; 9(1):2404. doi: 10.1038/s41467-018-04495-z.
Triscott J, Rubin MA; Prostate Power Play: Does Pik3ca Accelerate Pten-Deficient Cancer Progression? Cancer Discovery June 2018. 8.6: 682-685. doi: 10.1158/2159-8290.CD-18-0369
Lundquist MR, Goncalves MD, Loughran RM, Possik E, Vijayaraghavan T, Yang A, Pauli C, Ravi A, Verma A, Yang Z, et al. Phosphatidylinositol-5-Phosphate 4-Kinases Regulate Cellular Lipid Metabolism By Facilitating Autophagy. Molecular Cell. 2018; 70(3):531-544.e9. doi: 10.1016/j.molcel.2018.03.037.
Mateo J, Cheng HH, Beltran H, Dolling D, Xu W, Pritchard CC, Mossop H, Rescigno P, Perez-Lopez R, Sailer V, Kolinsky M, Balasopoulou A, Bertan C, Nanus DM, Tagawa ST, Thorne H, Montgomery B, Carreira S, Sandhu S, Rubin MA, Nelson PS, de Bono JS. Clinical Outcome of Prostate Cancer Patients with Germline DNA Repair Mutations: Retrospective Analysis from an International Study. European Urology. 2018; 73(5):687-693. doi: 10.1016/j.eururo.2018.01.010
Demichelis F, Rubin MA; The Genomics of Prostate Cancer: A Historic Perspective Cold Spring Harb Perspect Med. 2018 Apr 30. pii: a034942. doi: 10.1101/cshperspect.a034942.
Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang TH, Porta-Pardo E, Gao GF, Plaisier CL, Eddy JA, et al. The Immune Landscape of Cancer. Immunity. 2018; 48(4):812-830.e14. doi: 10.1016/j.immuni.2018.03.023
Armenia J, Wankowicz SAM, Liu D, Gao J, Kundra R, Reznik E, Chatila WK, Chakravarty D, Han GC, Coleman I, et al. The long tail of oncogenic drivers in prostate cancer, Nat Genet. 2018 Apr 2. doi: 10.1038/s41588-018-0078-z.
Sailer V, Schiffman MH, Kossai M, Cyrta J, Beg S, Sullivan B, Pua BB, Lee KS, Talenfeld AD, Nanus DM, Tagawa ST, Robinson BD, Rao RA, Pauli C, Bareja R, Beltran LS, Sigaras A, Eng KW, Elemento O, Sboner A, Rubin MA, Beltran H, Mosquera JM. Bone biopsy protocol for advanced prostate cancer in the era of precision medicine. Cancer. 2018; 124(5):1008-1015. doi: 10.1002/cncr.31173
McNair C, Xu K, Mandigo AC, Benelli M, Leiby B, Rodrigues D, Lindberg J, Gronberg H, Crespo M, De Laere B, Dirix L, Visakorpi T, Li F, Feng FY, de Bono J, Demichelis F, Rubin MA, Brown M, Knudsen KE. Differential impact of RB status on E2F1 reprogramming in human cancer. The Journal of Clinical Investigation. 2018; 128(1):341-358. doi: 10.1172/JCI93566
Gillessen S, Attard G, Beer TM, Beltran H, Bossi A, Bristow R, Carver B, Castellano D, Chung BH, Clarke N, et al. Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. European Urology. 2018; 73(2):178-211. doi: 10.1016/j.eururo.2017.06.002.
Shoag J, Liu D, Blattner M, Sboner A, Park K, Deonarine L, Robinson BD, Mosquera JM, Chen Y, Rubin MA, Barbieri CE. SPOP mutation drives prostate neoplasia without stabilizing oncogenic transcription factor ERG. The Journal of Clinical Investigation. 2018; 128(1):381-386. doi: 10.1172/JCI96551
D'Alfonso TM, Subramaniyam S, Ginter PS, Mosquera JM, Croyle J, Liu YF, Rubin MA, Shin SJ. Characterization of CD34-deficient myofibroblastomas of the breast. The Breast Journal. 2018; 24(1):55-61. doi: 10.1111/tbj.12835
See all publications
